Key facts
- One2Treat’s last known valuation is $2.8M (Sep 2025).
- It has raised $1.2M; the latest was Seed Round ($1.2M) in Sep 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for One2Treat
- ·The full record, as it builds
Funding rounds
No funding rounds for One2Treat are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About One2Treat
Developer of treatment decision solutions intended to develop methods and advanced software that enable an evaluation of treatment effects. The company offers transformative insights in clinical trial design, analysis, and market access evaluations, enabling clients to provide patients with personalized care that is tailored to their treatment preferences and unique needs.
- Sector
- Healthcare
- HQ
- Louvain-la-Neuve, Belgium
- Founded
- 2023
- Employees
- 13
- Website
- one2treat.com/
- Ownership
- Privately Held (backing)
One2Treat doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in One2Treat shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on One2Treat in its N-PORT filings yet. We sweep new filings monthly.